Currently, Lava Therapeutics is conducting a Phase I/II trial (NCT04887259) for LAVA-051, an antibody which binds both the Vδ2 chain and CD1d, allowing for selective stimulation of Vγ9Vδ2 T cells and NKT cells to target blood cancers such as chronic lymphocytic leukemia (CLL), MM, and AML (Table 1). This evidence concerns the gene CD1D and B-cell chronic lymphocytic leukemia.